Obesity redefined: GLP-1 drugs lead a new era of treating obesity as a chronic cardiometabolic disease
Obesity is being redefined as a chronic disease beyond BMI, with GLP-1 drugs like semaglutide and tirzepatide offering cardiovascular, renal, and liver benefits alongside weight loss, though only 25% of patients receive evidence-based treatment.
Quick Facts
What This Study Found
BMI inadequate for individual obesity assessment. GLP-1 drugs (semaglutide, tirzepatide) provide weight loss + cardiovascular, renal, liver benefits. <25% of obese individuals receive evidence-based treatment. Need for upstream, cardiometabolic-focused approach.
Key Numbers
How They Did This
Narrative review of evolving obesity definitions, management strategies, and cardiometabolic prioritization.
Why This Research Matters
The gap between effective treatments (especially GLP-1 drugs) and actual treatment delivery is enormous. Reframing obesity as a chronic disease requiring proactive medical management could improve access to transformative therapies.
The Bigger Picture
GLP-1 drugs are accelerating a paradigm shift in how medicine approaches obesity—from lifestyle advice to evidence-based chronic disease management with measurable cardiometabolic outcomes.
What This Study Doesn't Tell Us
Narrative review. US-centric healthcare perspective. Treatment access barriers (cost, insurance) not fully addressed.
Questions This Raises
- ?How can the treatment gap be closed?
- ?Should GLP-1 drugs be first-line for cardiometabolic obesity?
- ?Will precision medicine enable personalized obesity treatment selection?
Trust & Context
- Key Stat:
- <25% receive treatment Despite transformative GLP-1 drugs, less than one in four people with obesity receives evidence-based treatment—a critical access gap
- Evidence Grade:
- Narrative review synthesizing current evidence and guidelines.
- Study Age:
- Published in 2025.
- Original Title:
- Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.
- Published In:
- Advances in therapy, 42(11), 5341-5364 (2025)
- Authors:
- Singh, Vidhi, Sun, Jia, Cheng, Susan, Kwan, Alan C, Velazquez, Amanda
- Database ID:
- RPEP-13620
Evidence Hierarchy
Frequently Asked Questions
Why is BMI not enough to measure obesity?
BMI simply divides weight by height squared—it cannot distinguish between muscle and fat, does not measure where fat is stored, and fails to predict individual metabolic risk. Two people with the same BMI can have very different health risks depending on their fat distribution and metabolic function.
Why are so few people getting obesity treatment?
Less than 25% of people with obesity receive evidence-based care due to stigma, lack of trained physicians, cost barriers, insurance coverage gaps, and the persistent misconception that obesity is simply a lifestyle choice rather than a chronic medical condition.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13620APA
Singh, Vidhi; Sun, Jia; Cheng, Susan; Kwan, Alan C; Velazquez, Amanda. (2025). Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.. Advances in therapy, 42(11), 5341-5364. https://doi.org/10.1007/s12325-025-03352-y
MLA
Singh, Vidhi, et al. "Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.." Advances in therapy, 2025. https://doi.org/10.1007/s12325-025-03352-y
RethinkPeptides
RethinkPeptides Research Database. "Obesity as a Chronic Disease: A Narrative Review of Evolving..." RPEP-13620. Retrieved from https://rethinkpeptides.com/research/singh-2025-obesity-as-a-chronic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.